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factorial in etiology, there has been a concern about the link between therapy with 
mirtazapine, a heterocyclic antidepressant and the condition. This analysis character-
izes rhabdomyolysis signals for mirtazapine and other antidepressants. Methods: 
Adverse event reports submitted for antidepressants between 1997 and 2012 were 
retrieved from the FDA Adverse Event Reporting System (FAERS). Reporting Odds 
Ratio (ROR) and corresponding 95%CI (ROR05-ROR95) were estimated as a measure of 
disproportional reporting of rhabdomyolysis for individual antidepressants, includ-
ing mirtazapine. The MedDRA preferred term and drug generic names were used for 
event and drug measurement, respectively. Drug-event combinations with ROR05≥ 2.0 
are deemed as signals that warrant further review. Results: There were 1,178 rhab-
domyolysis reports submitted for all antidepressants, 85 reports were for mirtazap-
ine. Signals of rhabdomyolysis (ROR and 95%CI) were detected for mirtazapine (2.62, 
2.2-3.13), clomipramine (2.64, 2.07-3.36), and trimipramine (4.6, 2.64-8.0). There was 
disproportional reporting of rhabdomyolysis for the following agents albeit signal 
threshold was not reached (1< ROR05< 2): amoxapine, maprotiline, amitriptyline, 
rasagiline, citalopram, escitalopram, fluvoxamine, milnacipran, and venlafaxine. As 
a class, antidepressants were not associated with rhabdomyolysis risk (1.28, 0.91-2.02). 
Disproportionality measures were found for heterocyclics (2.10, 1.53-3.0), tricyclics 
(1.52, 1.3-2.34), nonselective monoamino oxidase inhibitors [MAOIs] (0.78, 0.42-1.5), 
selective MAOIs (1.68, 0.9-3.2), selective serotonin reuptake inhibitors [SSRIs] (1.2, 
1.0-1.5), serotonin-norepinephrine reuptake inhibitors [SNRIs] (1.08, 0.82-1.5), and 
other antidepressants (0.62, 0.43-1.1). ConClusions: Rhabdomyolysis is a potential 
risk associated with mirtazapine. In light of inherent limitations of spontaneous 
reporting systems, such as FAERS, signal evaluation activities in real-world data are 
required to further characterize rhabdomyolsysis risk in relation to mirtazapine and 
other antidepressant agents.
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objeCtives: Estimates of efficacy and safety are required for economic models 
developed for health technology assessments and provide guidance to decision-
makers regarding the benefit/risk profile of a drug. Studies synthesising clinical trial 
outcomes of atypical antipsychotics in schizophrenia often assume no dose-related 
heterogeneity. The objective of this analysis was to assess dose-related efficacy and 
weight changes after 6 weeks of treatment with lurasidone, an atypical antipsy-
chotic indicated for treatment of schizophrenia at an effective dose range of 20 mg 
to 160 mg/day. Methods: Random-effects meta-analysis was used to synthesize 
evidence from five, 6-week, randomized, double-blind, placebo-controlled studies 
of lurasidone in patients with acute schizophrenia. Outcome measures included 
6-week changes in Positive And Negative Syndrome Scale (PANSS) total score and 
weight (in kg). Results were pooled within and across the daily dose range (40-160 
mg/day) studied in these trials. Results: Pooled mean difference in PANSS total 
score was -8.38 (95% CI: -11.19, -5.56); and in weight was 0.51 kg (95% CI: 0.28, 0.75). 
Between-dose heterogeneity (I-squared= 61.2%, p= 0.006) was introduced by the 160 
mg dose, which was associated with greater treatment effect (mean difference 
-16.20; 95% CI: -21.10, -13.30). Moderate between-study heterogeneity was observed 
in the 40 mg and 120 mg doses (I-squared values were 52.8% and 33.2%, respectively). 
There was no evidence of between-dose or between-study heterogeneity in weight 
gain. ConClusions: Changes in PANSS total score from this meta-analysis sug-
gest that lurasidone in the daily dose range of 40-120 mg had similar efficacy versus 
placebo. The 160 mg daily dose was associated with greater reduction in PANSS total 
score versus placebo; however, this finding was based on evidence from a single 
study. This analysis found no evidence of a dose-related weight gain.
PMH3
anticHolinergic Medication use and risk of deMentia aMong 
elderly nursing HoMe residents witH dePression
Aparasu R.R.1, Chatterjee S1, Carnahan R.M.2, Chen H.1, Johnson M.L.1
1University of Houston, Houston, TX, USA, 2University of Iowa, Iowa city, IA, USA
objeCtives: Use of anticholinergic medications in the elderly can lead to adverse 
cognitive outcomes. This study examined the risk of dementia among elderly nurs-
ing home residents with depression using anticholinergic medications. Methods: 
A nested case-control study was conducted using 2007-2010 Medicare data from all 
states. Patients who had continuous coverage for Medicare Parts A, B and D and no 
HMO coverage during the study period or until death were included. The base cohort 
consisted of residents aged > 65 years, diagnosed with depression, and who did not 
have dementia in 2007 (Baseline Period). Cases were identified as patients who devel-
oped dementia following the baseline period. For each case, 4 age and sex-matched 
controls were selected using incidence density sampling. The primary outcome was 
diagnosis of dementia, between January 1, 2008 and December 31, 2010. Anticholinergic 
exposure was defined using the Anticholinergic Drug Scale (ADS). Prescription of level 
2/3 anticholinergic medications 30 days preceding the event date formed the primary 
exposure. Conditional logistic regression model stratified on matched case-control sets 
was performed to assess the dementia risk, after controlling for baseline sociodemo-
graphic variables and dementia risk factors. Results: The base cohort consisted of 
291,504 elderly residents with depression and without dementia diagnosis. The study 
sample included 49,966 cases diagnosed with dementia and 199,864 matched-controls. 
After adjusting for other covariates, high-level anticholinergic use was associated with 
significant risk of dementia (Relative Risk, RR 1.21; 95% CI, 1.18-1.23) compared to non-
use. The findings remained consistent across levels of anticholinergic potency (Level 
2, RR 1.42, 1.37-147; Level 3, RR 1.07, 1.09-1.15). ConClusions: Use of anticholinergic 
medications was associated with a higher risk of dementia compared to no use among 
elderly residents with depression. With increasing evidence regarding cognitive effects 
of anticholinergics, there is a significant need to optimize anticholinergic use, espe-
cially for those who are at-risk for dementia.
Methods for developing new Clinical Outcome Assessments (COAs) are well-estab-
lished and documented. While the COA development literature emphasizes the 
importance of linguistic and cultural equivalence, exact methods to achieve this are 
often not clearly presented. For multinational or multicultural studies, Simultaneous 
Item Development (SID) of a COA in all languages and cultural groups required for 
the research program is the most efficient approach to ensure valid COA data and 
interpretable results. This is because SID increases the likelihood the COA data col-
lected in multiple languages or cultures will be conceptually equivalent and culturally 
relevant.As published information explaining how to implement SID is limited, this 
presentation provides an overview of a purposeful and pragmatic (recognising the 
practical challenges associated with COA development) SID approach that incor-
porates both qualitative and quantitative methodologies.In our experience, SID is 
valuable at four stages of COA development: concept elicitation, item generation, 
cognitive testing, and content harmonization. Generally, SID is most efficient when 
a single reference or ‘core’ version is used throughout the four stages (typically the 
English language version for the UK or United States). Activities at each stage are 
managed by researchers fluent in the language for the core version. Their primary 
objective is to ensure that the core COA version has a clear conceptual framework 
that evolves in a consistent manner across language/culture versions at each stage 
so that measured concepts are equivalent in the different language versions.We will 
discuss how use of SID at each stage can aid researchers in developing COAs that are 
patient-centred, understandable, and content relevant across languages and cultures. 
Challenges commonly faced in SID of COA will be discussed as will practical solutions 
to these challenges.
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objeCtives: Determine growth and focal points for the development of health 
economics in Latin America, through the classification methodology proposed by 
Wagstaff and Culyer. Methods: From the results of the development of a literature 
review of health economics for Latin America in Scopus Database were classified 
the articles found in twelve groups of different general items, which were proposed 
by Wagstaff and Culyer in 2012, based on the Williams defining nodes 1989. It was 
analyzed the changes of production trends, as well as countries and institutions 
which developed the matter. Results: Production trend changes were found from 
1997, where an annual growth of over 50% of production for each year is evident, 
until 2003. With regard to issues of production about 52% focus on public health, as 
an item of the twelve general items, followed by the production of 20% in economic 
evaluation. Universities and institutions are presented with further development of 
the field, under the creation of courses, masters and specialization, and the creation 
of research groups. ConClusions: Taking as a reference these studies it is possible 
to find those areas that can be generated processes use and development of an entire 
scientific field, such as health economics, and not exhaust the use of a few tools on 
whims or vices of health systems.
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objeCtives: Resource modelling has been largely ignored in health technology 
assessment (HTA) and this paper argues the need for it to be considered as a separate 
set of analyses to deal with the issue of implementation and feasibility. Methods: 
Economic evaluation and budget impact models, which are the two economic analy-
ses that currently feed into HTA, are briefly described before highlighting their limita-
tions in informing issues of feasibility and implementation. Resource modelling is 
defined as the quantitative assessment of technology diffusion curves, their related resource 
requirements and their capacity constraints. The resource modelling examples from the 
literature include studies performed alongside traditional economic evaluation meth-
ods such as CEA or BIA and studies that were performed in the field of health care 
operational research. Results: Resource modelling can be performed using a num-
ber of different approaches. However, there are a number of general issues that need 
to be considered when choosing the appropriate resource modelling methodology 
and these include a) understand the different types of resources, b) the characteristics 
of different resource modelling techniques and, c) challenges for the generalising the 
estimation and validity of resource modelling results. ConClusions: Guidelines are 
provided as to when resource modelling is necessary i.e. when it should be used. The 
next issue is about the choice of methodology and this relates the level of resource 
use detail required. A related question is whether a standard exercise is enough for 
the whole jurisdiction or whether bespoke evaluations need to be performed for dif-
ferent local settings in the jurisdiction. Finally, the choice of data is also linked to the 
type of methodology chosen for resource modelling.
disease-sPecific studies
Mental HealtH – clinical outcomes studies
PMH1
MirtazaPine antidePressant tHeraPy is associated witH 
rHabdoMyolysis risk
Ali A.K.
Eli Lilly and company, Indianapolis, IN, USA
objeCtives: Among other factors, the breakdown of skeletal muscle fibers (rhabdo-
myolysis) is a leading cause of acute kidney failure. While rhabdomyolysis is multi-
